Prognostic Value Of PD-L1 Research Articles

Immunoscore based on PD-L1/PD-1 and CD8+ T cells as prognostic marker for stage II/III gastric cancer.

69 Background: PD-L1/PD-1 pathway has become an important target in tumor immunotherapy. However, the prognostic value of PD-L1/PD-1 for gastric cancer (GC) remains controversial due to the complexity of immune response. Therefore, comprehensive evaluation of PD-L1/PD-1 expression and CD8+T cells is necessary and superior to one factor in predicting survival. Methods: 166 patients with stage II-III GC were enrolled. Expression of PD-L1, PD-1, and CD8 protein in tumor tissues was examined by IHC staining, and their association with patient’s survival was analyzed by Kaplan-Meier method. Immunoscore classification was constructed using a scoring system, which was based on hazard ratios in a Cox proportional hazard analysis. Results: Expression of PD-L1 was found in 22.29% of immune cells (IC) and 38.55% of tumor cells (TC), while expression of PD-1 was found in 31.33% of IC. CD8High was detected in 41.57% patients. PD-L1+ and PD-1+ IC were both correlated with worse overall survival (OS) ( P=0.0009 and P=0.0004, respectively). In contrast, TC PD-L1+ was associated with better clinical outcomes, including Borrmann classification 0-1, lower AJCC stage, CD8High infiltration and better OS ( P<0.05). Furthermore, IC PD-L1, IC PD-1, CD8, and TC PD-L1 had independent prognostic significance after TNM stage adjustment, and we built an immunoscore system based on these immune factors. Patients with same stage could be further categorized into low-/median-/high-risk subgroups according to their immunoscores. Conclusions: Immunoscore based on comprehensive evaluation of PD-L1/PD-1 and CD8+ T cells can separate GC patients with same stage into different risk subgroups, and might provide suggestion for immunotherapy options in GC.

P2.04-020 Expression Patterns and Prognostic Value of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma: Topic: Thymic Malignancies Clinical and Translational

Thymic epithelial tumors (TETs) including thymoma (TA) and thymic carcinoma (TC) are rare, and little data are available to guide treatment. As the thymus plays a critical role in immune homeostasis, immunotherapy with checkpoint blockade is an attractive treatment strategy for patients with TET. Published data regarding the expression patterns and prognostic implications of PD-L1 expression in TET have yielded conflicting results, and have included limited data regarding PD-1 expression. A retrospective review was carried out at Ohio State University of 35 pts with TET, with tumor specimens available at our institution from 2000 – 2010. PD-1 and PD-L1 expression was assessed by immunohistochemistry on tumor samples (utilizing PD-1 clone: NAT105 and PD-L1 clone:22C3 antibodies), and graded 0-5 according to expression (0 – no expression, 5 – high expression). Clinicopathologic characteristics assessed included age, grade, stage, overall survival, smoking status, and diagnosis of myasthenia gravis. PD-1 and PD-L1 expression were assessed in 35 pts, including 32 pts with thymoma and 3 pts with thymic carcinoma. PD-L1 expression was detected in 83% (29/35) tumor samples, including 100% (3/3) of thymic carcinoma pts and 81% (26/32) of thymoma pts. PD-1 expression was detected in 77% (27/35) of samples, including 33% (1/3) of thymic carcinoma pts and 81% (26/32) thymoma pts. High levels (IHC >/= 3) of PD-L1 were detected in 57% (20/35) of pts, and high levels of PD-1 expression (IHC >/= 3) were detected in 31% (11/35) pts. A nonsignificant trend towards poorer overall survival was seen in patients with PD-L1 expression (p=0.097, log-rank test). Unlike prior studies, PD-L1 expression was not associated with higher grade tumors (B2, B3, C) or higher stage at diagnosis. Interestingly, high PD-1 expression was significantly associated with lower grade tumors (p = 0.031), but not overall survival. Expression of PD-L1 and PD-1 was not significantly associated with stage at diagnosis, smoking, recurrence, or diagnosis of myasthenia gravis. This study confirms high expression of PD-L1 and PD-1 in TETs, including thymoma and thymic carcinoma. PD-L1 expression was associated with a trend towards shorter overall survival. The high proportion of patients with high PD-L1 and PD-1 expression supports the use of anti PD-1 therapies in this patient population, and prospective trials are needed to assess PD-L1 and PD-1 as predictive and prognostic biomarkers in TET.

Integrative assessment of expression and prognostic value of PDL1, IDO, and kynurenine in 371 primary soft tissue sarcomas with genomic complexity.

11008Background: Programmed death-ligand 1 (PD-L1), Indole 2,3 dioxygenase (IDO) or Kynurenine (K) expression has uncertain or unknown prognostic value in soft tissue sarcoma (STS)and may vary with...

High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma.

PD-L1 has been widely demonstrated to contribute to failed antitumor immunity. Blockade of PD-L1 with monoclonal antibody could modulate the tumor immune environment to augment immunotherapy. PD-L1 expression is also detected in several types of cancer and is associated with poor prognosis. However, the prognostic role of PD-L1 in oral squamous cell carcinoma (OSCC) is still controversial. Our aim was to determine the role of PD-L1 in the prognosis of OSCC patients to identify its potential therapeutic relevance. PD-L1 immunoreactivity was analyzed by immunohistochemistry in 305 cancer specimens from primary OSCC patients. The medium follow-up time after surgery was 3.8 years (range from 0.1 to 11.1 years). The prognostic value of PD-L1 on overall survival was determined by Kaplan-Meier analysis and Cox proportional hazard models. Higher PD-L1 expression is more likely in tumor tissues of female than male OSCC patients (P = 0.0062). Patients with distant metastasis also had high PD-L1 expression (P = 0.0103). Multivariate analysis identified high PD-L1 expression as an independent risk factor in males and smokers (males: hazard ratio = 1.556, P = 0.0077; smokers: hazard ratio = 2.058, P = 0.0004). We suggest that PD-L1 expression, determined by IHC staining, could be an independent prognostic marker for OSCC patients who are male or who have a smoking habit.